Quantcast

Latest SSM-N-8 Regulus Stories

2014-02-19 08:31:20

-RG-012 is an anti-miR Targeting microRNA-21 for the Treatment of Alport Syndrome, a Life-Threatening, Genetic Kidney Disease with No Approved Therapy- LA JOLLA, Calif., Feb. 19, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has advanced its orphan disease portfolio with the nomination of its second microRNA candidate for clinical...

2014-02-13 08:30:40

-Martin Beaulieu, Ph.D. Brings Extensive Diagnostic Assay Development Experience- LA JOLLA, Calif., Feb. 13, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the appointment of Martin Beaulieu, Ph.D. as the head of Regulus microMarkers(TM), a research and development division of Regulus designed to support the expansion of its innovative...

2014-02-04 08:34:28

-Mr. Szekeres Brings Extensive Strategic and Transactional Deal Experience- LA JOLLA, Calif., Feb. 4, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the addition of David Szekeres to its executive management team as Chief Business Officer and General Counsel. Most recently, Mr. Szekeres served as Deputy General Counsel, Chief M&A Counsel...

2014-02-03 16:25:26

LA JOLLA, Calif., Feb. 3, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus, will present a company overview at the 16(th) Annual BIO CEO & Investor Conference being held at the Waldorf-Astoria Hotel in New York City on Tuesday, February 11, 2014 at 11:30 am EST. Dr....

2014-01-13 08:27:16

-Regulus microMarkers(TM) Designed to Support Regulus' Therapeutic Pipeline, its Collaborators and Strategic Partners- LA JOLLA, Calif., Jan. 13, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it has established Regulus microMarkers(TM), a new research and development division of Regulus designed to support the expansion of its innovative...

2014-01-07 16:25:27

LA JOLLA, Calif., Jan. 7, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., President and Chief Executive Officer of Regulus, will present a company overview at the 32nd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2014 at 8:30 AM PST at the Westin St. Francis Hotel in San Francisco, CA....


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related